Moberg Pharma: Making good progress

Research Update

2018-05-24

07:30

The development in the OTC business was solid in 1Q18 and beat our expectations in almost every aspect. With a positive development in 1Q18 and a stronger USD, we raise our forecasts and our fair value to SEK 64 (62).

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.